The benefit of secondary prevention with oat fiber in reducing future cardiovascular event among CAD patients after coronary intervention

• Published in: Scientific reports Vol. 9; no. 1; p. 3091
• Main Authors: Wu, Jia-Ru, Leu, Hsin-Bang, Yin, Wei-Hsian, Tseng, Wei-Kung, Wu, Yen-Wen, Lin, Tsung-Hsien, Yeh, Hung-I, Chang, Kuan-Cheng, Wang, Ji-Hung, Wu, Chau-Chung, Chen, Jaw-Wen
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 28.02.2019; Nature Publishing Group
• Subjects: 692/4019/2776; 692/700/459/1994; 9/10; Cardiovascular diseases; Cerebral infarction; Dietary fiber; High density lipoprotein; Humanities and Social Sciences; Inflammation; Low density lipoprotein; multidisciplinary; Myocardial infarction; Science; Science (multidisciplinary); Serum levels; Triglycerides
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-019-39310-2

There is limited information about the association between oat fiber intake and future cardiovascular events in CAD patients after coronary intervention for secondary prevention. This study enrolled 716 patients after coronary intervention in clinical stable status from the CAD cohort biosignature study. Patients were analyzed according to whether the presence of regular oat fiber intake during the follow-up period, and the association with endpoints including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and revascularization procedures were analyzed. The average follow-up period is 26.75 ± 8.11 months. Patients taking oat fiber were found to have lower serum levels of LDL, triglycerides, ratio of TC/HDL, as well as lower inflammatory markers values. After adjusting for confounders in the proportional hazard Cox model, oat fiber intake was associated with a lower risk of future revascularization (HR = 0.54, 95% CI 0.35–0.85; p = 0.007), and lower risk of major adverse cardiovascular events (HR = 0.62, 95% CI 0.43–0.88; p = 0.008), suggesting the association of oat fiber use and lower risk of future adverse event in CAD patients after coronary intervention.